International Clinical Trial: A Phase Id, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Bridging Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of XKH001 in Healthy Adult Caucasian Participants

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (ACTRN12626000935336) titled 'A Phase Id, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Bridging Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Immunogenicity of XKH001 in Healthy Adult Caucasian Participants' on July 29.

Study Type: Interventional

Study Design: Purpose: Treatment Allocation: Randomised controlled trial Masking: Blinded (masking used) Assignment: Other Type of endpoint: Pharmacokinetics

Primary Sponsor: MDCECRO AUSTRALIA PTY. LTD.

Condition: type 2 inflammatory diseases type 2 inflammatory diseases Inflammatory and Immune System - Other inflammatory or immune system disorders

Intervent...